Home About us Contact
|
Home About us Contact | ||
|
|
||
Drug Safety (drug + safety)
Terms modified by Drug Safety Selected AbstractsRegional Editor Sought for Pharmacoepidemiology and Drug Safety for the Asia-Pacific Region, Middle East and AfricaPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 1 2010Article first published online: 24 DEC 200 No abstract is available for this article. [source] Erratum: Hepatitis B vaccination and multiple sclerosis: a data mining perspectivePHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 1 2008Manfred Hauben MD Pharmacoepidemiology and Drug Safety 2007; 16: 943,945 DOI: 10.1002/pds.1420 If has come to our attention that page 945 of this Letter to the Editor contained an error in the text. The published sentence currently reads from line 3: For example12 reported "impressively large" observed/expected ratios for the association of leukotriene receptor modifiers with Churg-Strauss syndrome when they applied a data mining methodology to the US FDA AERS database, while13 failed to find any association using a nested case-control study in US managed care organization databases. It should read: For example DuMouchel et al.12 reported "impressively large" observed/expected ratios for the association of leukotriene receptor modifiers with Churg-Strauss syndrome when they applied a data mining methodology to the US FDA AERS database, while Harrold et al.13 failed to find any association using a nested case-control study in US managed care organization databases. We apologise for this anomaly. [source] Retracted: A quantitative approach to benefit-risk assessment of medicines,part 2; the practical application of a new model Filip Mussen, Sam Salek, Stuart WalkerPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 10 2007Ronald D. Mann Editor-in-Cheif The following article from Pharmacoepidemiology and Drug Safety, ,A Quantitative Approach to Benefit-Risk Assessment of Medicines,Part 2; The Practical Application of a New Model' by Mussen F, Salek S & Walker S (Pharmacoepidemiol Drug Saf 2007; 16: S16,S41 DOI: 10.1002/pds.1434) has been retracted by agreement between the authors, the Journal's Editor-in-Chief and John Wiley & Sons, Ltd. The retraction has been agreed due to overlap between this article and an internal report published by CMR International Institute; ,Benefit-Risk Assessment Model Developing a Structured Approach to Decision Making'. [source] Retracted:A quantitative approach to benefit-risk assessment of medicines , part 2: the practical application of a new model,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue S1 2007Filip Mussen PhD Purpose Retraction: The following article from Pharmacoepidemiology and Drug Safety, A Quantitative Approach to Benefit-Risk Assessment of Medicines - Part 2; The Practical Application of a New Model by Mussen F, Salek S & Walker S (Pharmacoepidemiol Drug Saf 2007;16:S16-S41 DOI:10.1002/pds.1434) has been retracted by agreement between the authors, the Journal Editor-in-Chief and John Wiley & Sons, Ltd. The retraction has been agreed due to overlap between this article and an internal report published by CMR International Institute; Benefit-Risk Assessment Model Developing a Structured Approach to Decision Making. [source] The trade-off between cardiovascular and gastrointestinal effects of rofecoxibPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 9 2005Stefan R. Florentinus PharmD The original article to which this Erratum refers was published in Pharmacoepidemiology and Drug Safety, 14 (7) 2005, 437,441. No Abstract. [source] The trade-off between cardiovascular and gastrointestinal effects of rofecoxib,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 7 2005Stefan R. Florentinus PharmD Abstract An Erratum has been published for this article in Pharmacoepidemiology and Drug Safety 14(9), 2005, 669. Background The cyclooxygenase-2 (COX-2) inhibitor rofecoxib was registered in 1999. By 2000, the first reports were published indicating that the agent was possibly associated with an increased risk of myocardial infarction. Since then a surge of data supporting this association has become available. To interpret these data it is essential to ascertain the cardiovascular risk profile of users of rofecoxib relative to other non-steroidal anti-inflammatory drug (NSAID) recipients. Objective To assess differences in cardiovascular risk between starters of rofecoxib versus starters of any other NSAID. Setting Data sampled from a representative research network of Dutch general practitioners (GPs) in 2001. Design New users (starters) of rofecoxib were compared to starters of any other NSAID, unmatched and matched on age, gender, and indication nested in the cohort of the second Dutch National Survey of General Practice. Results A total of 40.4% of patients starting on rofecoxib had cardiovascular co-morbidity. Patients starting on rofecoxib were twice more likely to have a history of gastrointestinal (GI) morbidity, compared to patients starting on other NSAIDs (ORadj,=,2.09; 95%CI,=,1.65,2.66). These patients were also more likely to have cardiovascular co-morbidity (OR,=,1.90; 95%CI,=,1.60,2.24) compared to recipients of rofecoxib with no GI co-morbidity. Cardiovascular morbidity was present at the time of rofecoxib exposure in over 61% of carriers of a composite risk profile including age 60 years or older, GI co-morbidity and diagnosis of rheumatoid arthritis and osteoarthritis. Conclusions In general, a typical recipient of an NSAID is aged and carrier of a serious cardiovascular risk profile. Selective prescribing of rofecoxib to provide claimed gastroprotection, indirectly and unintentionally resulted in prescribing rofecoxib in a population with high frequencies of cardiovascular morbidities. Copyright © 2005 John Wiley & Sons, Ltd. [source] Pharmacoepidemiology and Drug Safety, Volume 11, Issue 3.PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 4 2002Table of Contents The original article to which this Erratum refers was published in Pharmacoepidemiology and Drug Safety Volume 11, Issue 3 [source] Latest news and product developmentsPRESCRIBER, Issue 19 2008Article first published online: 16 OCT 200 ARBs less effective than ACE inhibitors? The efficacy of angiotensin-II receptor blockers (ARBs) in preventing cardiovascular events in high-risk patients has been challenged by the findings of a large randomised trial (Lancet 2008 published online; doi 10.1016/ S0140-6736(08)61242-8). In the TRANSCEND trial, 5926 patients with cardiovascular disease or diabetes with end-organ damage who could not tolerate ACE inhibitor therapy were randomised to placebo or telmisartan (Micardis) 80mg per day in addition to standard therapies. After 56 months, mean blood pressure was lower with telmisartan (by 4.0/2.2mmHg) but there were no significant differences between telmisartan and placebo in the risk of cardiovascular events , a composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Hospitalisation for cardiovascular reasons were slightly but significantly reduced by telmisartan (33 vs 30 per cent). MHRA: fentanyl patch errors potentially fatal Errors in dosing, accidental exposure and enhanced absorption from heat exposure have resulted in life-threatening and fatal incidents with transdermal fentanyl, warns the MHRA in its latest Drug Safety Update (September 2008). There is also evidence that fentanyl patches are being prescribed for nonlicensed indications, including treatment of opioid-naive patients. Other topics in this issue include managing adverse reactions to HPV vaccine and an update on new cases of progressive multifocal leucoencephalopathy associated with natalizumab (Tysabri). Call for DURG research The Drug Utilisation Research Group is inviting abstracts for oral and poster presentations at its 20th annual meeting on 5 February 2009. The theme of the morning session is ,Whose prescribing budget is it anyway?'. Abstracts will be accepted on any drug utilisation research studies and will be published in the Journal of Pharmacoepidemiology and Drug Safety. Information is available at www.durg.org.uk the deadline for submissions is 1 December. Early bromocriptine no benefit in Parkinson's Initiating treatment of Parkinson's disease with the dopamine agonist bromocriptine offers no long-term benefit compared with levodopa, the UK Parkinson's Disease Research Group trial has shown (Neurology 2008;71:474-80). After 14 years' follow-up of 166 patients, there were no differences in the prevalence of motor complications, dementia or mortality, but levodopa was associated with superior scores of disability and physical functioning. The authors say the belief that early dopamine agonist treatment is neuroprotective in Parkinson's disease should be abandoned. Ezetimibe with statin cancer risk ,not credible' Analysis of data pooled from two large trials provides ,no credible evidence' that ezetimibe (Ezetrol) is associated with an increased risk of cancer when added to statin therapy (N Engl J Med 2008 published online; doi 10.1056/NEJMsa0806603). A possible link with increased risk of cancer with ezetimibe plus simvastatin was suggested by the SEAS trial (N Engl J Med 2008 published online; doi 10.1056/NEJMoa 0804602). This hypothesis was tested in two trials involving more than 20 500 patients over 1.0-2.7 years. There was no excess of cancer overall or at particular sites; cancer deaths were more numerically but not significantly higher with ezetimibe and there was no evidence of increased risk with duration of treatment. Telmisartan provides no advantage after stroke Adding telmisartan (Micardis) to standard treatment after ischaemic stroke does not reduce morbidity, US investigators report (N Engl J Med 2008 published online; doi 10.1056/NEJMoa 0804593). A total of 20 332 patients with recent ischaemic stroke were randomised to placebo or telmisartan 80mg per day in addition to antiplatelet therapy and antihypertensive agents. After 2.5 years, blood pressure was 3.8/2.0mmHg lower in patients taking telmisartan but there were no significant differences from placebo in the risks of recurrent stroke, cardiovascular events or new-onset diabetes. Copyright © 2008 Wiley Interface Ltd [source] Accounting for Multiplicities in Assessing Drug Safety: A Three-Level Hierarchical Mixture ModelBIOMETRICS, Issue 2 2004Scott M. Berry Summary. Multiple comparisons and other multiplicities are among the most difficult of problems that face statisticians, frequentists, and Bayesians alike. An example is the analysis of the many types of adverse events (AEs) that are recorded in drug clinical trials. We propose a three-level hierarchical mixed model. The most basic level is type of AE. The second level is body system, each of which contains a number of types of possibly related AEs. The highest level is the collection of all body systems. Our analysis allows for borrowing across body systems, but there is greater potential,depending on the actual data,for borrowing within each body system. The probability that a drug has caused a type of AE is greater if its rate is elevated for several types of AEs within the same body system than if the AEs with elevated rates were in different body systems. We give examples to illustrate our method and we describe its application to other types of problems. [source] Developing an optimal approach to global drug safetyJOURNAL OF INTERNAL MEDICINE, Issue 4 2001R. Balkrishnan Abstract.,Balkrishnan R, Furberg CD (Wake Forest University School of Medicine, Winston-Salem, NC, USA). Developing an optimal approach to global drug safety (Review). J Intern Med 2001: 250; 271,279. An increasing number of media reports on a number of marketed drugs withdrawn because of harmful effects, a scientific report on epidemic proportions of serious adverse drug reactions in hospitalized patients, and a disturbing report on medical mistakes that includes medication errors have recently all brought drug safety into intense focus and placed it under greater scrutiny. Concerted efforts are now being made to understand the causes of drug safety problems and to find ways to reduce their frequency. An international symposium, ,Developing an Optimal Approach to Drug Safety' was held at Wake Forest University in the Fall of 2000 to identify the issues and solutions to extant problems in this area. This report summarizes the resulting discussions of global postmarketing surveillance initiatives and describes efforts to reduce medication errors, and improve global communication about drug safety. [source] Posters Monday 14 July Drug safety and toxicologyFUNDAMENTAL & CLINICAL PHARMACOLOGY, Issue 2008Article first published online: 28 JUN 200 First page of article [source] Drug safety: who is responsible?INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Issue 2 2007B. Pitt No abstract is available for this article. [source] Drug safety , important to us all!JOURNAL OF INTERNAL MEDICINE, Issue 4 2001LARS ERIK BÖTTIGER MD No abstract is available for this article. [source] Perceived adverse drug reactions among non-institutionalized children and adolescents in GermanyBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Issue 3 2010Hildtraud Knopf WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Drug safety in paediatric medication is a public health concern. According to previous studies, the incidence of adverse drug reactions (ADRs) varies greatly from 0.7% to 2.7% among paediatric outpatients and from 2.6% to 18.1% among paediatric inpatients. Little has been reported on the risks of drug use in the general child population. WHAT THIS STUDY ADDS Our study showed that the prevalence of perceived ADRs in Germany was 0.9% among non-institutionalized children in general and 1.7% among children who had used at least one medicine within the 7 days before the medical interview. Perceived ADRs in the general child population were clustered with gastrointestinal disorders and subcutaneous tissue disorders. They appeared to be mild and at the lower limits of the range reported in other studies. Health surveys covering the use of a diverse range of drugs might be suitable for computing ADR prevalence and for identifying risk factors among non-institutionalized children. They should be taken into account together with other pharmacovigilance systems. AIMS Little has been reported on the risks of drug use in the general child population. This study investigated perceived adverse drug reactions (ADRs) among non-institutionalized children in Germany. METHODS All medicines used in the last 7 days before the medical interview were recorded among the 17 450 children aged 0,17 years who participated in the 2003,06 German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Perceived ADRs were reported by the children's parents and confirmed by trained medical professionals during the medical interview. RESULTS One hundred and fifty-seven medicines were involved in the occurrence of 198 perceived ADRs in 153 patients. This corresponded to 1.1% of total used drugs, 0.9% (95% confidence intervals 0.7, 1.1%) of all children, and 1.7% (1.4, 2.1%) of children treated with medications. About 40% of all perceived ADRs involved gastrointestinal disorders and 16% involved skin tissue disorders. Perceived ADRs were most frequently reported in relation to drugs acting on the nervous system (25.8%), followed by systemic anti-infectives (18.7%) and drugs acting on the respiratory system (16.2%). Risk factors for perceived ADRs included older age groups, polypharmacy (,2) and a poor health status. CONCLUSION Perceived ADRs in the general child population were clustered with gastrointestinal disorders and subcutaneous tissue disorders. They appeared to be mild and at the lower limits of the range reported in other studies. Health surveys covering the use of a diverse range of drugs might be suitable for computing ADR prevalence and identifying risk factors among non-institutionalized children. They should be taken into account together with other pharmacovigilance systems. [source] The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO databaseFUNDAMENTAL & CLINICAL PHARMACOLOGY, Issue 2 2008A. Bate Abstract After market launch, new information on adverse effects of medicinal products is almost exclusively first highlighted by spontaneous reporting. As data sets of spontaneous reports have become larger, and computational capability has increased, quantitative methods have been increasingly applied to such data sets. The screening of such data sets is an application of knowledge discovery in databases (KDD). Effective KDD is an iterative and interactive process made up of the following steps: developing an understanding of an application domain, creating a target data set, data cleaning and pre-processing, data reduction and projection, choosing the data mining task, choosing the data mining algorithm, data mining, interpretation of results and consolidating and using acquired knowledge. The process of KDD as it applies to the analysis of spontaneous reports can be exemplified by its routine use on the 3.5 million suspected adverse drug reaction (ADR) reports in the WHO ADR database. Examples of new adverse effects first highlighted by the KDD process on WHO data include topiramate glaucoma, infliximab vasculitis and the association of selective serotonin reuptake inhibitors (SSRIs) and neonatal convulsions. The KDD process has already improved our ability to highlight previously unsuspected ADRs for clinical review in spontaneous reporting, and we anticipate that such techniques will be increasingly used in the successful screening of other healthcare data sets such as patient records in the future. [source] Pharmacogenetics and personalised medicineFUNDAMENTAL & CLINICAL PHARMACOLOGY, Issue 5 2002Werner Kalow ABSTRACT The traditional concern of pharmacogenetics was Mendelian (monogenic) variation, which visibly affected some drug responses. Pharmacogenetics was broadened by the observation that multifactorial genetic influences, in conjunction with environmental factors, usually determine drug responses. Variability of gene expression, a new theme of the science of genetics, also affects pharmacogenetics; for example, enhanced enzyme activity does not necessarily indicate a mutation, but may be the consequence of a drug-induced enhancement of gene expression. Methodological advances permit the conversion of pharmacogenetics into the broad practice of pharmacogenomics; this improves the possibility of identifying genetic causes of common diseases, which means establishing new drug targets, thereby stimulating the search for new drugs. While the main medical effect of pharmacogenetics was an improvement of drug safety, pharmacogenomics is hoped to improve drug efficacy. On the way to personalized medicine, we may stepwise improve the chances of choosing the right drug for a patient by categorizing patients into genetically definable classes that have similar drug effects (as, for example, human races, or any population group carrying a particular set of genes). It is wise to expect that, even after we have reached the goal to establish personalized medicine, we will not have eliminated all uncertainties. [source] Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasiaINTERNATIONAL JOURNAL OF UROLOGY, Issue 9 2009Taiji Tsukamoto Objectives: To assess the efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia (BPH). Methods: This was a randomized, double-blind, placebo-controlled, parallel-group study. A total of 378 subjects with clinical BPH having an International Prostate Symptom Score (IPSS) of 8 points or greater, a prostate volume of 30 mL or greater, and a maximal urinary flow rate (Qmax) of 15 mL/s or less were randomized to receive placebo or dutasteride once daily for 52 weeks. Subjects were stratified according to tamsulosin use at baseline. The numbers of subjects with and without tamsulosin use were 242 and 136, respectively. IPSS, Qmax, prostate volume and drug safety were evaluated. Results: Continued improvement in IPSS was noted in the dutasteride group, and dutasteride significantly decreased IPSS compared with placebo. At week 52, dutasteride significantly improved Qmax and prostate volume compared with placebo. Drug-related sexual function events in the dutasteride group were infrequent and generally were not treatment limiting. Conclusions: Dutasteride improves urinary symptoms and flow rate and reduces prostate volume. In Japanese men with BPH, it is effective and generally well tolerated during the one-year treatment period. [source] Developing an optimal approach to global drug safetyJOURNAL OF INTERNAL MEDICINE, Issue 4 2001R. Balkrishnan Abstract.,Balkrishnan R, Furberg CD (Wake Forest University School of Medicine, Winston-Salem, NC, USA). Developing an optimal approach to global drug safety (Review). J Intern Med 2001: 250; 271,279. An increasing number of media reports on a number of marketed drugs withdrawn because of harmful effects, a scientific report on epidemic proportions of serious adverse drug reactions in hospitalized patients, and a disturbing report on medical mistakes that includes medication errors have recently all brought drug safety into intense focus and placed it under greater scrutiny. Concerted efforts are now being made to understand the causes of drug safety problems and to find ways to reduce their frequency. An international symposium, ,Developing an Optimal Approach to Drug Safety' was held at Wake Forest University in the Fall of 2000 to identify the issues and solutions to extant problems in this area. This report summarizes the resulting discussions of global postmarketing surveillance initiatives and describes efforts to reduce medication errors, and improve global communication about drug safety. [source] Sequential case series analysis for pharmacovigilanceJOURNAL OF THE ROYAL STATISTICAL SOCIETY: SERIES A (STATISTICS IN SOCIETY), Issue 1 2009Mounia N. Hocine Summary., The self-controlled case series method is used to evaluate drug safety, particularly the safety of paediatric vaccines with respect to rare adverse reactions. We propose a group sequential version of the method for prospective surveillance of drug safety. We focus on the surveillance of new vaccines. We develop methods that are based on the sequential probability ratio test applied at predetermined surveillance intervals, using both simple and composite alternative hypotheses. We investigate the properties of the methods analytically in a simple setting and by simulations in more realistic scenarios. The methods are applied to data on influenza vaccine and Bell's palsy, and to data on measles, mumps and rubella vaccine and bleeding disorders. [source] Open-Label Exploration of an Intravenous Nalbuphine and Naloxone Mixture as an Analgesic Agent Following Gynecologic SurgeryPAIN MEDICINE, Issue 6 2007Assaf T. Gordon MD ABSTRACT Objective., The purpose of this series was to explore a 12.5:1 fixed-dose ratio of an intravenous nalbuphine and naloxone mixture (NNM) for use in patients following gynecologic surgery. Design and Patients., Open-label, nonrandomized case series. The first series was a dose-ranging investigation for 12 patients following elective total abdominal hysterectomy or myomectomy. In this series, fentanyl was used for intraoperative analgesia, and patients were assigned to a lower NNM (2.5 mg/0.2 mg) or to a higher NNM (5 mg/0.4 mg) dose group. The second series evaluated the fixed dose of 5 mg nalbuphine/0.4 mg naloxone for four patients undergoing ambulatory gynecologic procedures. In the second series, no opioid agents were administered intraoperatively to eliminate the possibility of mu-opioid reversal by naloxone postoperatively. Outcome Measures., Pain control was assessed using a Verbal Pain Scale (0,10). Vital signs, side effects, and adverse events were recorded to determine drug safety. Results., In the first series, there were no adverse events; however, each patient required rescue medication (either morphine or fentanyl). In the second series, two of the four patients reported a reduction in pain following drug administration and did not require any further analgesic agents in the 3-hour postoperative period. One patient had an asymptomatic lowering of heart rate after receiving the drug. Conclusion., Additional research of the unique combination therapy of nalbuphine and naloxone is warranted to further determine its potential clinical efficacy and safety. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 3 2010Article first published online: 24 FEB 2010 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization,,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 11 2009Liyan Liu MD Abstract Purpose Resources for studying inflammatory bowel disease (IBD) are needed in evaluations of drug safety including traditional drugs and new biologics agents. We developed an IBD registry, with ascertainment from computerized visit information. Objective We sought to characterize the positive predictive value (PPV) of IBD case-finding using computerized data compared with chart review. Methods We identified 2906 persons aged 89 years or younger with one or more IBD diagnoses in computerized visit data during the period of 1996,2002. The diagnosis of IBD was confirmed through chart review. Adopting chart review as the gold standard, the validity of computerized encounter data to determine IBD was estimated. Results Among the 2906 study subjects with one or more ICD-9 diagnosis codes of 555 or 556 in computerized data, 81% were confirmed as having IBD by chart review. Defining cases as those who underwent two or more visits without regard to diagnostic procedures or drug utilization maximized the correct classification of cases (PPV, 95%). Conclusions The quality of IBD diagnoses in computerized data is adequate to meet the aims of a wide range of research studies. Copyright © 2009 John Wiley & Sons, Ltd. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 9 2009Article first published online: 18 AUG 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 7 2009Article first published online: 26 JUN 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 6 2009Article first published online: 2 JUN 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 5 2009Article first published online: 20 APR 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 5 2008Article first published online: 29 APR 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 4 2008Article first published online: 26 MAR 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 12 2007Article first published online: 27 NOV 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] Current awareness: Pharmacoepidemiology and drug safetyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 7 2007Article first published online: 28 JUN 200 In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti-infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non-steroidal Anti-inflammatory Agents; 7 CNS Agents; 8 Anti-neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator-Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti-inflammatory Agents - Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source] | ||||||||||||||||||||||||||||